Loading... please wait

Policy to Practice: Nodes of the Psychedelic Medicine Ecosystem

with lead programming SPONSOR

logo color vertical%401x - Policy to Practice: Nodes of the Psychedelic Medicine Ecosystem

SpeakerS:

Sherry Rais, CEO, Enthea
Isaac Gilmore, Chief of Staff, TREAT California
Alex Enchin, Co-Founder, HOLOS
Jeremy Gardner, Managing Partner, Mystic Ventures

Key takeaways & next steps:

  • There appears to be applications of psychedelic treatments not just in the treatment of anxiety, depression, and PTSD but also in the pursuit of optimizing the mental health of people without such severe symptoms.
  • Psychedelic therapy can lead to differences in one’s relationship with their external environment as well as regulate hormones, meaning that this therapy should be carried out in conjunction with—rather than separately from—traditional therapy.
  • These treatments can have a significant impact on the lives of veterans suffering from PTSD. Different approaches to scheduling and research will help prevent veterans from leaving the country in search of such treatments.
  • With 6 out of 10 employees currently suffering from anxiety or depression, there appears to be clear applications for these treatments for employers. Enthea provides companies with the option of offering substances such as psilocybin as a workplace benefit.
  • Steps should be taken to reduce stigma and encourage education around the use of psychedelic treatments, particularly the data and testimonials. 
  • For the benefit of self education, individuals can make use of the resources found at Microdose.buzz, as well as the recent Michael Pollan Netflix documentary How to change your mind.
  •  

“Many people preceding psychedelics or even therapy just feel helpless. We have that problem in our nation right now and just that one phone call, that one little conversation, “hey how are you doing?”—it can make all the difference.”

 
Sherry Rais, CEO, Enthea

“Our nation’s greatest warriors have to leave their own soil for treatment and that is unequivocally unacceptable.”

 
Isaac Gilmore, Chief of Staff, TREAT California

“We need leaders, from the business world and government, to have experiences with these medicines to understand how they work.”

 
Alex Enchin, Co-Founder, HOLOS

“The biggest barrier right now is scheduling, because at schedule one, mushrooms, LSD, and MDMA are the same as crack cocaine and heroin, so you can’t get government funding for research.”

 
Jeremy Gardner, Managing Partner, Mystic Ventures

Copyright © 2024 Concordia.

All rights reserved. Concordia is a registered 501(c)(3) nonprofit, nonpartisan organization.